Anthos' blood thinner cuts the risk of bleeding amid race to develop safer anticoagulants - Endpoints News
endpts.comSubmitted by endpointsnews6292 in health
PHILADELPHIA — An anticoagulant from Anthos Therapeutics substantially cut the risk of bleeding compared to Xarelto in a mid-stage safety study. The Anthos drug is part of an up-and-coming class of investigational anticoagulants that clinicians and companies …